Severe pyogenic infections in patients taking infliximab. A regional cohort study;Infections sévères à pyogènes chez les patients traités par infliximab. Étude d'une cohorte régionale

Revue du Rhumatisme (Edition Francaise)

Volumn 72, Issue 7, 2005, Pages 650-655

  Maillard, Hélène ^a   Ornetti, Paul ^a   Grimault, Laurent ^b   Ramon, Jean François ^c   Ducamp, Sylvie Melac ^d   Saidani, Tahar ^e   Tavernier, Christian ^a   Maillefert, Jean Francis ^a,f  

^a HÔPITAL DU BOCAGE   (France)

^b Service de Rhumatologie   (France)

^c centre hospitalier Saint Morand   (France)

^d CH du pays du Gier   (France)

^e Service de Médecine IV   (France)

^f UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Ankylosing spondylitis; Anti TNF ; Pyogenic infections; Rheumatoid arthritis; Side effects

Indexed keywords

EID: 22544445248     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2004.09.002     Document Type: Article

References (28)

1. G. Harriman, L.K. Harper, and T.F. Schaible Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFα treatment Ann. Rheum. Dis. 58 suppl I 1999 I61 I64
2. M.C. Hochberg, J.K. Tracy, and R.H. Flores "Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate Ann. Rheum. Dis. 60 Suppl 3 2001 iii51 iii54
3. P.E. Lipsky, D.M. Van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, and J.R. Kalden Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N. Engl. J. Med. 343 2000 1594 1602
4. J. Brandt, J. Sieper, and J. Braun Infliximab in the treatment of active and severe ankylosing spondylitis Clin. Exp. Rheumatol. 20 Suppl 28 2002 S106 S110
5. J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, and G. Burmester Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial Arthritis Rheum 48 2003 2224 2233
6. S. Schnarr, J.G. Kuipers, and H. Zeidler Anti-tumour necrosis factor (TNF)-α therapy in undifferentiated spondyloarthropathy Clin. Exp. Rheumatol. 20 Suppl 28 2002 S126 S129
7. T.I. Temekonidis, Y. Alamanos, S.N. Nikas, D.V. Bougias, A.N. Georgiadis, and P.V. Voulgari Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study Ann. Rheum. Dis. 62 2003 1218 1220
8. T.F. Schaible Traitement de maladies inflammatoires:: sécurité d'emploi à long terme de l'infliximab Press Med. 30 2001 610 623
9. W.J. Shergy, R.A. Isern, D.A. Cooley, J.L. Harshbarger, J.E. Huffstutter, and G.M. Hugues Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis J. Rheumatol. 29 2002 667 677
10. R. Day Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis Lancet 359 2002 540 541
11. M.H. Weisman What are the risks of biologic therapy in rheumatoid arthritis? An update on safety J. Rheumatol. 29 Suppl 65 2002 33 38
12. J.J. Gomez-Reino, L. Carmona, V.R. Valverde, E.M. Mola, and M.D. Montero Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicentre-active surveillance report Arthritis Rheum. 48 2003 2122 2127
13. S. Roth, E. Delmont, P. Heudier, R. Kaphan, E. Cua, and J. Castela Anticorps anti-TNFα (infliximab) et tuberculose: à propos de trois cas Rev. Med. Interne 23 2002 312 316
14. GTI (Groupe Tuberculose et Infliximab) Afssaps Recommendations about the prevention and management of tuberculosis in patients taking infliximab Joint Bone Spine 69 2002 170 172
15. S. Harney, F.D. O'Shea, and O. Fitzgerald Peptostreptococcal pericarditis complicating anti-tumour necrosis factor alpha treatment in rheumatoid arthritis Ann. Rheum. Dis. 6 2002 653 654
16. S. Kroesen, A.F. Widmer, A. Tyndall, and P. Hasler Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy Rheumatology 42 2003 617 621
17. F.G. Matzkies, B. Manger, M. Schmitt-Haendle, T. Nagel, H.G. Kraetsch, and J.R. Kalder Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab Ann. Rheum. Dis. 62 2003 81 82
18. I. Olivieri, A. Padula, L. Armignacco, V. Sabatella, and M. Mancino Septic arthritis caused by moraxella catarrhalis associated with infliximab treatment in a patient with undifferentiated spondarthritis Ann. Rheum. Dis. 63 2004 105 106
19. T. Ellerin, R.H. Rubin, and M.E. Weinblatt Infections and anti-tumor necrosis factor alpha therapy Arthritis Rheum. 48 2003 3013 3022
20. D.E. Furst, F.C. Breedveld, J.R. Kalden, J.S. Smolen, G.D. Burmester, and M. Dougados Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (may 2003) Ann. Rheum. Dis. 62 suppl 2 2003 ii2 ii9
21. British Society for Rheumatology Guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis: report of a working party of the british society for rheumatology www.msecportal.org/portal/editorial/ PublicPages/bsr/536883013/1.doc
22. R. Maini, E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, and M. Weisman Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial Lancet 354 1999 1932 1939
23. S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein, L.F. Mayer, S. Schreiber, and J.F. Colombel Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541 1549
24. M.F. Doran, C.S. Crowson, G.R. Pond, W.M. O'Fallon, and S.E. Gabriel Predictors of infection in rheumatoid arthritis Arthritis Rheum. 46 2002 2294 2300
25. M.A. Fitzcharles, D. Clayton, and H.A. Menard The use of infliximab in academic rheumatology practice: an audit of early clinical experience J. Rheumatol. 29 2002 2525 2530
26. D. Baeten, E. Kruithof, F. Van den Bosch, N. Van den Bossche, A. Herssens, and H. Mielants Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease? Ann. Rheum. Dis. 62 2003 829 834
27. M. Flendrie, M.C. Creemers, P.M. Welsing, A.A. Den Broeder, and P.L. Van Riel Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis Ann. Rheum. Dis. 62 suppl 2 2003 ii30 ii33
28. Update with rheuma https://wwwNFforRAguid.